Aegerion Pharmaceuticals Inc $32.54

down 0.00


27/8/2014 04:00 PM  |  NASDAQ : AEGR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get AEGR Trend Analysis - it has underperformed the S&P 500 by 85%

Partner Headlines

  1. Aegerion Pharmaceuticals Announces Resolution Of Warning Letter for JUXTAPID ...

    Benzinga
  2. Markets Open Higher; Priceline Issues Downbeat Profit Forecast

    Benzinga
  3. US Stock Futures Signal Higher Start On Wall Street

    Benzinga
  4. Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR

    GuruFocus
  5. The FED Continues To Taper; Indices Rebound Slightly

    Benzinga
  6. Twitter Jumps On Upbeat Results; DreamWorks Shares Slide

    Benzinga
  7. Markets Mixed; Sprint Posts Profit

    Benzinga
  8. Benzinga's Volume Movers

    Benzinga
  9. Morning Market Movers

    Benzinga
  10. Benzinga's Top #PreMarket Gainers

    Benzinga
  11. Stocks Hitting 52-Week Lows

    Benzinga
  12. 5-Star Biotech Stock Watch: Aegerion Pharmaceuticals

    Benzinga
  13. Stocks Hitting 52-Week Lows

    Benzinga
  14. Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS

    GuruFocus
  15. Four CEOs Reporting Large Insider Buys

    GuruFocus
  16. Morning Market Losers

    Benzinga
  17. UPDATE: Aegerion Pharma Commences Phase 3 Clinical Trial in Japan, Will ...

    Benzinga
  18. Aegerion's JUXTAPID Capsules Approved in Mexico for Treatment of Homozygous ...

    Benzinga
  19. Leerink Swann Reiterates on Aegerion Pharmaceuticals as Weakness is Overdone

    Benzinga
  20. Canaccord Genuity Reiterates on Aegerion Pharmaceuticals as Selling is ...

    Benzinga
  21. Aegerion Pharmaceuticals Presents Data From Phase 3 Extension Study of ...

    Benzinga
  22. UPDATE: Deutsche Bank Reiterates on Aegerion Pharmaceuticals Following ...

    Benzinga
  23. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies ...

    Benzinga
  24. Benzinga's Top Pre-Market Gainers

    Benzinga
  25. $176,000 or $295,00 a Year: Bizarre World of Orphan Drugs

    YCharts
  26. Mid-Morning Market Update: Markets Heading Down, Dendreon Rockets Upwards

    Benzinga
  27. UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion ...

    Benzinga
  28. Aegerion Pharmaceuticals Grants Stock Options to Purchase 55K Shares

    Benzinga
  29. My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List

    GuruFocus
  30. UPDATE: Jefferies Raises PT to $29 on Aegerion Pharmaceuticals on Juxtapid ...

    Benzinga
  31. Canaccord Genuity Reiterates Buy Rating, $27 PT on Aegerion Pharmaceuticals

    Benzinga
  32. Stocks To Watch For December 26, 2012

    Benzinga
  33. Aegerion's Juxtapid OK'd

    IBD
  34. UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Aegerion ...

    Benzinga
  35. FDA Approves Aegerion's' JUXTAPID Capsules for Homozygous Familial Hypercholesterolemia

    Benzinga
  36. Benzinga's M&A Chatter for Friday December 7, 2012

    Benzinga
  37. Aegerion Pharma Reserves Shares for Inducement Stock Options

    Benzinga
  38. Aegerion Pharmaceuticals Issued Patent by European Patent Office

    Benzinga
  39. BioMarin Stock Soars On Positive Drug Data

    IBD
  40. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Aegerion ...

    Benzinga
  41. FDA EMDAC Recommends Approval of Lomitapide for Treatment of Homozygous ...

    Benzinga
  42. FDA Advisers Vote 13-2 that Aegerion Data Sufficient For Approval

    Benzinga
  43. Benzinga Mid-Afternoon Market Update

    Benzinga
  44. Benzinga Mid-Day Market Update

    Benzinga
  45. Benzinga Mid-Afternoon Market Update

    Benzinga
  46. Benzinga Mid-Morning Market Update

    Benzinga
  47. Options Alert - Aegerion Pharmaceuticals

    Benzinga
  48. UPDATE: J.P. Morgan Initiates Coverage on Aegerion Pharmaceuticals with ...

    Benzinga
  49. Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review ...

    Benzinga
  50. Health Care Sector Wrap

    FoxBusiness
Trading Center